PM
KPTI icon

Parametrica Management’s Karyopharm Therapeutics KPTI Stock Holding History

Parametrica Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-898
Closed -$139K – 101
2021
Q2 		$139K Sell
898
-5,295
-85% -$768K 0.1% 90
2021
Q1 		$925K Buy
+6,193
New +$1.3M 0.44% 50

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parametrica Management's KPTI Position: Q3 2021 in Review

Parametrica Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 898 shares — an estimated $139K sold.

Parametrica Management first reported a position in KPTI in Q1 2021 and held it in 2 quarters. The position peaked at $925K in Q1 2021. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Parametrica Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametrica Management sold 898 Karyopharm Therapeutics shares in Q3 2021, an estimated $139K.
  • Parametrica Management first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 2 quarters.
  • Parametrica Management's Karyopharm Therapeutics position peaked at $925K in Q1 2021.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Parametrica Management's 13F filing for Q3 2021, filed 12 Nov 2021.